Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

Ellenberger, David; Eichstädt, Kerstin; Flachenecker, Peter; Friede, Tim; Haas, Judith; Kleinschnitz, Christoph; Pöhlau, Dieter; Rienhoff, Otto; Stahmann, Alexander; Zettl, Uwe K.

doi:10.1016/j.msard.2018.07.040

Cited by 8 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The GMSR conducts retrospective analysis for a variety of MS-related research questions. These include demographic studies, measurements of care availability, causal inferences but also pharmacovigilance studies and epidemiological assessments 6 , 22 – 25 . Most analyses are performed using R 26 .…”

Section: Resultsmentioning

confidence: 99%

“…Treatment guidelines for chronic diseases like MS are often established based upon limited evidence regarding the real-world efficacy and safety of disease modifying treatments (DMT) 5 , 6 . Additionally, long-term therapeutic effects beyond the duration of phase III clinical trials, and treatment strategy studies are frequently unavailable 7 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry

Ohle

Ellenberger

Flachenecker

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

In 2001, the German Multiple Sclerosis Society, facing lack of data, founded the German MS Registry (GMSR) as a long-term data repository for MS healthcare research. By the establishment of a network of participating neurological centres of different healthcare sectors across Germany, GMSR provides observational real-world data on long-term disease progression, sociodemographic factors, treatment and the healthcare status of people with MS. This paper aims to illustrate the framework of the GMSR. Structure, design and data quality processes as well as collaborations of the GMSR are presented. The registry’s dataset, status and results are discussed. As of 08 January 2021, 187 centres from different healthcare sectors participate in the GMSR. Following its infrastructure and dataset specification upgrades in 2014, more than 196,000 visits have been recorded relating to more than 33,000 persons with MS (PwMS). The GMSR enables monitoring of PwMS in Germany, supports scientific research projects, and collaborates with national and international MS data repositories and initiatives. With its recent pharmacovigilance extension, it aligns with EMA recommendations and helps to ensure early detection of therapy-related safety signals.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry

Ohle

Ellenberger

Flachenecker

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…current data from the DMSG registry), even if no evidence-based studies are available. [47][48][49][50] Recommendation 3: [51][52][53] In addition to preventing acute episodes of the disease, prophylactic therapy may reduce the risk of long-term neurologic deterioration or secondary progression. Due to the slow course of MS, this therapeutic goal cannot be investigated in randomized trials.…”

Section: What Is the Benefit Of Dmt In Patients With Rms Compared With No Treatment/treatment With Another Disease-modifying Drug?mentioning

confidence: 99%

“…current data from the DMSG registry), even if no evidence-based studies are available. [47][48][49][50] Recommendation 3:…”

Section: What Is the Benefit Of Dmt In Patients With Progressive Ms (Ppms Or Spms) Compared With No Treatment?mentioning

confidence: 99%

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Wiendl

Gold

Berger

et al. 2021

Ther Adv Neurol Disord

Self Cite

122

101

View full text Add to dashboard Cite

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).

show abstract

“…B. [ 30 , 97 ], aktuelle Daten des DMSG-Registers), auch wenn keine evidenzbasierten Studien vorliegen.…”

Section: Kernfragen Und Empfehlungen Zur Therapeutischen Interventionunclassified

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

et al. 2021

Self Cite

View full text Add to dashboard Cite

ZusammenfassungDie Multiple Sklerose ist eine komplexe, autoimmun vermittelte Erkrankung des zentralen Nervensystems, charakterisiert durch inflammatorische Demyelinisierung sowie axonalen/neuronalen Schaden. Die Zulassung verschiedener verlaufsmodifizierender Therapien und unser verbessertes Verständnis der Krankheitsmechanismen und -entwicklung in den letzten Jahren haben die Prognose und den Verlauf der Erkrankung deutlich verändert. Diese Aktualisierung der Behandlungsempfehlung der Multiple Sklerose Therapie Konsensus Gruppe konzentriert sich auf die wichtigsten Empfehlungen für verlaufsmodifizierende Therapien der Multiplen Sklerose im Jahr 2021. Unsere Empfehlungen basieren auf aktuellen wissenschaftlichen Erkenntnissen und gelten für diejenigen Medikamente, die in weiten Teilen Europas, insbesondere in den deutschsprachigen Ländern (Deutschland, Österreich, Schweiz), zugelassen sind.

show abstract

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

Cited by 8 publications

References 4 publications

Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry

Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Contact Info

Product

Resources

About